Status:
UNKNOWN
COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Solid Tumor
Hematologic Malignancy
Eligibility:
All Genders
18+ years
Brief Summary
In the context of malignant disease, it is likely that vaccine efficacy and immunogenicity depends on the type of pathology, stage of the disease, immunosuppression induced by the treatments, in addit...
Detailed Description
During the visit carried out as part of the follow-up, participation in this study will be proposed to any patient who is treated for a malignant disease (solid or hematological tumors) within the uni...
Eligibility Criteria
Inclusion
- Patients with malignant disease undergoing treatment at Saint Louis Hospital or Bichat Hospital (for chest cancer)
- with chemotherapy
- with chemotherapy + Immunotherapy
- with immunotherapy
- with targeted therapies
- with radiotherapy
- in the event of radiation pneumonitis after radiotherapy for lung cancers
- after pneumonectomy for lung cancer
- Patient informed and having expressed their non-opposition to participating in this research
Exclusion
- Patient with a contraindication to Sars-Cov2 vaccination
Key Trial Info
Start Date :
January 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04776005
Start Date
January 22 2021
End Date
February 1 2024
Last Update
January 3 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint-Louis Hospital, AP-HP
Paris, France, 75010
2
Bichat Hospital, AP-HP
Paris, France, 75018